10-K: UroGen Pharma's 2025 Annual Report: Revenue Growth & Pipeline

UroGen Pharma's 2025 annual report details significant revenue growth driven by Jelmyto and Zusduri sales, alongside pipeline advancements and increased operating losses.

Summary

• Revenue increased to $109.8 million in 2025 from $90.4 million in 2024, primarily due to the commercial launch of Zusduri and increased Jelmyto sales.
• Net loss widened to $153.5 million in 2025 from $126.9 million in 2024, and the accumulated deficit reached $959.7 million as of December 31, 2025.
• Operating expenses rose significantly, with selling and marketing expenses increasing by $23.9 million to $99.1 million, and research and development expenses increasing by $10.0 million to $67.1 million.
• Zusduri (mitomycin) for intravesical solution received FDA approval on June 12, 2025, for recurrent low-grade intermediate risk NMIBC, with an estimated annual treatable population of 82,000 in the U.S. and a potential market opportunity over $5.0 billion.
• Jelmyto (mitomycin) for pyelocalyceal solution, approved in April 2020 for low-grade UTUC, continues commercialization, with long-term follow-up data showing a median duration of response of 47.8 months.
• The company acquired UGN-501, a next-generation investigational oncolytic virus, in February 2025, with plans to initiate a Phase 1 clinical study by the end of 2026.
• UGN-103 and UGN-104, next-generation formulations of Zusduri and Jelmyto, are advancing, with UGN-103's Phase 3 UTOPIA trial completing enrollment in July 2025 and UGN-104's Phase 3 trial initiated in June 2025.
• Development of UGN-301 was discontinued in November 2025 due to its clinical profile not meeting internal benchmarks for advancement to Phase 2.
• The company refinanced its loan agreement with Pharmakon on February 26, 2026, securing a senior secured term loan facility of up to $250.0 million, with $200.0 million immediately available for refinancing and general corporate purposes.
• A patent infringement lawsuit against Teva Pharmaceuticals related to Jelmyto is ongoing, with a bench trial scheduled for October 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as moderately negative. While revenue growth and pipeline advancements are positive, the significant increase in net loss and negative operating cash flow, coupled with ongoing reliance on external financing and a patent infringement lawsuit, indicate substantial financial challenges and execution risks.

Positives

• FDA approval of Zusduri on June 12, 2025, for recurrent low-grade intermediate risk NMIBC, marking it as the first and only FDA-approved non-surgical treatment for this indication.
• Significant revenue growth in 2025, with total revenue reaching $109.8 million, up from $90.4 million in 2024, driven by both Jelmyto and the new Zusduri sales.
• Positive long-term durability data for Jelmyto, with a median duration of response of 47.8 months in the long-term follow-up study of the Phase 3 Olympus trial.
• Strong clinical trial results for Zusduri, including a 79.6% complete response rate at three months in the ENVISION trial and an 82.3% 12-month duration of response.
• Successful acquisition of UGN-501, a next-generation investigational oncolytic virus, enhancing the immuno-uro-oncology pipeline.
• Advancement of UGN-103 and UGN-104 into Phase 3 clinical trials, with UGN-103 showing a 77.8% three-month complete response rate consistent with prior trials.
• FDA acceptance of Investigational New Drug Applications (INDs) for UGN-103 (April 2024) and UGN-104 (February 2025), facilitating clinical development.
• Extension of Jelmyto admixture's in-use period from 8 hours to 96 hours (four days) by the FDA in September 2022, improving convenience and flexibility.
• Assignment of permanent J-codes for both Jelmyto (effective January 1, 2021) and Zusduri (effective January 1, 2026) by CMS, aiding reimbursement and market access.
• Jelmyto granted New Technology Ambulatory Payment Classification (APC) effective October 1, 2023, ensuring separate payment for a period.
• Successful completion of patient enrollment for the Phase 3 UTOPIA trial of UGN-103 in July 2025.
• Positive results from a Phase 3b study demonstrating the feasibility of Zusduri home administration by a qualified home health professional, with 75% of patients achieving a complete response.

Negatives

• Net loss increased to $153.5 million in 2025 from $126.9 million in 2024, indicating a widening financial deficit.
• Accumulated deficit reached $959.7 million as of December 31, 2025, reflecting sustained historical losses.
• Net cash used in operating activities increased significantly to $162.4 million in 2025 from $96.8 million in 2024.
• Operating expenses increased substantially, with selling and marketing expenses up by $23.9 million and research and development expenses up by $10.0 million.
• Discontinuation of UGN-301 development in November 2025 due to its clinical profile not meeting internal benchmarks for advancement to Phase 2, leading to termination of the Agenus license agreement.
• Ongoing patent infringement lawsuit against Teva Pharmaceuticals regarding Jelmyto, which could lead to generic competition if unsuccessful in securing court relief after April 2027.
• Dependence on single-source suppliers for critical raw materials and components (e.g., mitomycin API from Teva Pharmaceuticals Industries Ltd., hydrogel from Isotopia Molecular Imaging Ltd.), posing supply chain risks.
• Exposure to geopolitical, economic, and military instability in Israel, where research and development facilities and key vendors are located, potentially disrupting operations.
• Covenants under the Prepaid Forward Contract with RTW and the Pharmakon loan agreement restrict the company's ability to borrow additional capital and engage in certain financial activities.
• The company has limited experience in marketing and distributing products as an organization, posing risks to successful commercialization of new products.

Risks

• May require additional financing to fund operations and achieve goals; failure to obtain capital could force delays or termination of product development and commercialization efforts.
• Highly dependent on the successful commercialization of approved products, Jelmyto and Zusduri, with market opportunities potentially smaller than anticipated.
• Limited experience in marketing and distributing products, subject to risks in commercialization of Jelmyto, Zusduri, and any future approved product candidates.
• Jelmyto, Zusduri, and product candidates may fail to achieve broad physician adoption and market acceptance necessary for commercial success.
• Significant competition from existing treatments and other pharmaceutical companies developing drugs in urology and uro-oncology.
• Clinical drug development is lengthy, expensive, and uncertain; earlier trial results may not predict future outcomes, and trials may fail to demonstrate safety and efficacy.
• Reliance on third-party subcontractors and single-source suppliers for raw materials and manufacturing, posing risks of supply disruption, increased costs, and regulatory non-compliance.
• International trade policies, including tariffs, sanctions, and trade barriers, may adversely affect business, financial condition, and results of operations.
• Product liability lawsuits could result in substantial liabilities and require limiting commercialization of products.
• Failure to attract and retain senior management and key personnel could hinder successful product development and commercialization.
• Information technology systems or data, or those of third parties, could be compromised, leading to regulatory actions, litigation, financial losses, and business disruptions.
• Changes in U.S. patent law could diminish the value of patents, impairing the ability to protect products.
• Trade secrets may not have sufficient intellectual property protection, and misappropriation could erode competitive position.
• Claims of intellectual property infringement by third parties could adversely affect the business, leading to costly litigation or licensing requirements.
• If the FDA concludes that requirements for product candidates are not as expected, approval pathways could be significantly longer, costlier, and more complex.
• Current and future healthcare legislation, including reform measures, may increase limitations on reimbursement, rebates, and other payments, adversely affecting third-party coverage and profitability.
• Approved products are subject to ongoing regulatory obligations and review, which may result in additional expenses, limit or withdraw approval, and subject the company to penalties for non-compliance.
• Difficulty in profitably selling products if coverage and reimbursement are limited by government authorities and/or third-party payor policies.
• Operations in Israel are subject to geopolitical, economic, and military instability, which could adversely affect results.
• Provisions of Israeli law and articles of association may delay or prevent mergers or acquisitions.
• Difficulty in enforcing U.S. court judgments against the company or its officers/directors in Israel, or asserting U.S. securities laws claims in Israel.
• Shareholder rights and responsibilities governed by Israeli law, which differs from U.S. law.
• Actions of activist shareholders could negatively affect business and stock value.
• Adverse developments in the financial services industry could impact business operations and financial condition.
• Unstable market, economic, and geo-political conditions may have serious adverse consequences on business and share price.
• Business could be negatively impacted by environmental, social, and corporate governance matters or related reporting.

Future Outlook

The company anticipates submitting an NDA for UGN-103 in the second half of 2026, with potential FDA approval in 2027. Enrollment in the Phase 3 trial of UGN-104 is expected to be completed by the end of 2026. A Phase 1 clinical study for UGN-501 is planned to be initiated by the end of 2026. The company expects to continue incurring losses and negative cash flows as it executes its strategy, including the ongoing commercial launch of Zusduri, continued commercialization of Jelmyto, and further research and development activities. Additional financing will be required to fund operations and achieve goals.

Management Comments

• We are a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers.
• We believe Zusduri has the potential to become the new standard of care for adults with recurrent low-grade intermediate risk NMIBC as the first and only FDA-approved non-surgical treatment.
• We are focused on changing the way urothelial cancers are treated, an area in which there has been no significant advancements in recent years.
• We are committed to helping patients access Jelmyto.
• We initiated a strategic, multi-faceted approach to promote broad adoption and patient access to Zusduri, leveraging our existing customer-facing team.
• We anticipate submitting an NDA for UGN-103 in the second half of 2026 with potential FDA approval in 2027.
• Our development plan for UGN-501 is advancing and IND-enabling studies are currently ongoing, with the goal of initiating a Phase 1 clinical study by the end of 2026.
• While the Phase 1 clinical study of UGN-301 confirmed proof of concept for our proprietary RTGel technology as a viable platform for local delivery of complex immunotherapies, UGN-301's overall clinical profile did not meet our internal benchmarks for advancement to Phase 2.
• We are focused on driving growth through business development and geographic footprint expansion focusing on sustained nearer-term revenue growth, innovation, high unmet need and cost-effective value creation.

Industry Context

StockSavvy.ai notes UroGen Pharma's focus on urothelial and specialty cancers with its RTGel technology positions it uniquely against traditional surgical methods. The recent FDA approval of Zusduri and pipeline advancements in UGN-103, UGN-104, and the acquired UGN-501 indicate a strategic expansion within this niche, contrasting with competitors who primarily focus on high-grade, metastatic, or muscle-invasive cancers. The discontinuation of UGN-301 reflects a disciplined pipeline management approach, prioritizing candidates with stronger clinical profiles. The company's ability to secure J-codes and New Technology APC for its approved products is crucial for market access in a cost-conscious healthcare environment.

Comparison to Industry Standards

• Jelmyto is the first and only FDA-approved non-surgical treatment for low-grade UTUC, addressing a significant unmet medical need where radical nephroureterectomy (RNU) was often the standard.
• Zusduri is the first and only FDA-approved medication for adults with recurrent low-grade intermediate risk NMIBC, offering a non-surgical alternative to repeated trans-urethral resection of bladder tumor (TURBT) procedures.
• RTGel technology significantly extends drug dwell time in the urinary tract (e.g., 6 hours for mitomycin in UTUC vs. approximately 5 minutes for standard aqueous mitomycin), allowing for potentially higher drug concentrations (up to 8 mg/mL with RTGel vs. 0.5 mg/mL in water).
• Current standard of care for low-grade intermediate risk NMIBC, TURBT, is associated with high recurrence rates (up to 70%) and risks (35% adverse events within 90 days, 14% greater risk of death for 2-4 procedures vs. 1). Zusduri aims to mitigate these issues.
• In high-grade NMIBC, competitors include Ferring Pharmaceuticals' Adstiladrin (approved 2022), Johnson & Johnson's INLEXZO (approved September 2025), Keytruda (pembrolizumab, approved 2020), Valstar (valrubicin, approved 1998), and Bacillus Calmette-Guérin (BCG, approved 1989). UroGen's UGN-501 aims to introduce a novel oncolytic virus approach in this aggressive cancer type.

Management Changes

Legal Proceedings

• A lawsuit was filed on April 2, 2024, in the U.S. District Court for the District of Delaware against Teva Pharmaceuticals, Inc. and Teva Pharmaceuticals USA, Inc., alleging infringement of U.S. Patent Numbers 9,040,074, 9,950,069, and 12,268,745 related to Jelmyto.
• The lawsuit seeks a permanent injunction preventing U.S. market entry of Teva's generic product prior to the expiry of the patents.
• Certain counts alleging infringement of U.S. Patent Numbers 9,040,074 and 9,950,069, and Teva's counterclaims seeking declaratory judgment of their invalidity, were dismissed with prejudice and as moot, respectively, by order dated January 12, 2026.
• A bench trial for the remaining claims is scheduled for October 2026.
• No ANDA may be finally approved by the FDA until the expiration of Orphan Drug Exclusivity covering JELMYTO in April 2027. If the company is unsuccessful in securing court relief, Jelmyto may face immediate generic competition after April 2027.

Related Party Transactions

• Entities affiliated with Arie Belldegrun, the Chair of the Board of Directors, held promissory notes of IconOVir Bio, Inc., entitling them to approximately 28.3% of the $4.0 million purchase price paid to IconOVir for the acquisition of UGN-501 (formerly ICVB-1042) in February 2025.

Stakeholder Impact

• Shareholders: Potential for dilution from future equity offerings, impact from fluctuating share price due to market conditions and company performance, and potential adverse tax consequences if classified as a PFIC.
• Patients: Continued access to innovative non-surgical treatments for urothelial cancers (Jelmyto, Zusduri) and potential new therapies in the pipeline (UGN-103, UGN-104, UGN-501).
• Healthcare Providers: New treatment options for low-grade UTUC and recurrent low-grade intermediate risk NMIBC, with efforts to ensure seamless preparation and administration, and reimbursement support.
• Employees: Continued growth and expansion of the organization, but also risks related to attracting and retaining skilled personnel in a competitive industry.
• Suppliers: Continued reliance on third-party and single-source suppliers for critical raw materials and manufacturing, with associated risks of disruption.
• Creditors (Pharmakon, RTW): Obligations under loan agreements and prepaid forward contracts, with security interests granted over product assets.

Next Steps

• Complete the ongoing ENVISION trial to further characterize the clinical benefit of Zusduri.
• Provide the FDA updates on Duration of Response (DOR) for all Zusduri patients with ongoing Complete Responses (CRs) until recurrence, progression, death, loss to follow-up, or 63 months after first instillation.
• Submit an NDA for UGN-103 in the second half of 2026, with potential FDA approval in 2027.
• Complete enrollment in the Phase 3 trial of UGN-104 by the end of 2026.
• Initiate a Phase 1 clinical study for UGN-501 by the end of 2026, following ongoing IND-enabling studies.
• Conduct a long-term follow-up study for UGN-103 patients remaining in CR for up to five years after treatment initiation.
• Use commercially reasonable efforts to develop and commercialize one ICVB Product (UGN-501) until February 14, 2035, or the first commercial sale, whichever is earlier.

Key Dates

Recommendation

The company has achieved significant milestones with the FDA approval and commercial launch of Zusduri, and continues to advance its pipeline with UGN-103, UGN-104, and the acquired UGN-501. However, the substantial increase in net losses and negative operating cash flows, coupled with ongoing reliance on external financing and a patent infringement lawsuit for Jelmyto, present considerable financial risks. The long-term potential of its RTGel technology and new products is promising, but current financial performance and competitive pressures warrant a cautious "hold" stance for investors until there is clearer evidence of sustained profitability and successful market penetration.

Keywords

Urothelial Cancer, NMIBC, UTUC, RTGel, Jelmyto, Zusduri, UGN-103, UGN-104, UGN-501, Biotechnology, Oncology, Drug Delivery, FDA Approval, Clinical Trials, Pharmaceuticals, Mitomycin, Orphan Drug, Patent Litigation, SEC Filing